Skip to main content
SpringerLink
Log in

IMMUNOTHERAPY

Tumors evading CARs—the chase is on

  • News & Views
  • Published:

From Nature Medicine

View current issue Submit your manuscript

Acquired resistance to CD19-targeted CAR T cell therapy can occur through mutations in the CD19 gene or after insertion of a chimeric antigen receptor (CAR) into leukemia cells, resulting in the adjacent receptor being masked by the CAR.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: CD19 antigen escape from CAR T cell therapy.

References

  1. Majzner, R. G. & Mackall, C. L. Cancer Discov. https://doi.org/10.1158/2159-8290.CD-18-0442 (2018).

    Article  Google Scholar 

  2. Orlando, E. J. et al. Nat. Med. https://doi.org/10.1038/s41591-018-0146-z (2018).

  3. Ruella, M. et al. Nat. Med. https://doi.org/10.1038/s41591-018-0201-9 (2018).

  4. Sotillo, E. et al. Cancer Discov. 5, 1282–1295 (2015).

  5. Sommermeyer, D. et al. Leukemia 31, 2191–2199 (2017).

    Article  CAS  Google Scholar 

  6. Bagashev, A. et al. Mol. Cell. Biol. https://doi.org/10.1128/MCB.00383-18 (2018).

  7. Fischer, J. et al. J. Immunother. 40, 187–195 (2017).

    Article  CAS  Google Scholar 

  8. Ali, S. A. et al. Blood 128, 1688–1700 (2016).

    Article  CAS  Google Scholar 

  9. Cho, J. H., Collins, J. J. & Wong, W. W. Cell 173, 1426–1438.e11 (2018).

    Article  CAS  Google Scholar 

  10. Jackson, H. J., Rafiq, S. & Brentjens, R. J. Nat. Rev. Clin. Oncol. 13, 370–383 (2016).

    Article  CAS  Google Scholar 

  11. Avanzi, M. P. et al. Cell Reports 23, 2130–2141 (2018).

    Article  CAS  Google Scholar 

  12. Rafiq, S. et al. Nat. Biotechnol. 36, 847–856 (2018).

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Sarwish Rafiq & Renier J. Brentjens

  2. Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Sarwish Rafiq & Renier J. Brentjens

  3. Department of Pharmacology, Weill Cornell Graduate School of Medical Sciences, New York, NY, USA

    Renier J. Brentjens

Authors
  1. Sarwish Rafiq
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Renier J. Brentjens
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Renier J. Brentjens.

Ethics declarations

Competing interests

R.J.B. is a cofounder of and receives royalties from Juno Therapeutics.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rafiq, S., Brentjens, R.J. Tumors evading CARs—the chase is on. Nat Med 24, 1492–1493 (2018). https://doi.org/10.1038/s41591-018-0212-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-018-0212-6

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation